Amphista Therapeutics Raises $7.5m Series A Round to Advance Targeted Protein Degradation Assets in Cancer

GLASGOW, Scotland, April 7, 2020 /PRNewswire/ -- Amphista Therapeutics, a biopharmaceutical company creating first-in-class cancer therapeutics that harness the body's natural processes to selectively and efficiently degrade and remove disease causing proteins, today announced the closing...

from PR Newswire: https://ift.tt/2UPajdW